Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma

Abstract

Adenoviruses are efficient gene delivery vehicles but have broad native tropism. To this end, finding ways to target this virus specifically to carcinomas has become an important focus of cancer gene therapy. Transductional and transcriptional forms of targeting have been used with promising results in ovarian carcinoma. Therefore, we combined both forms of targeting to investigate the effect on the specificity and efficiency of transgene expression in this disease. We used the tissue-specific SLPI promoter and the ovarian cancer associated targeting adaptor protein, sCARfC6.5. This bispecific protein contains the coxsackie-adenovirus receptor ectodomain and a single-chain antibody specific for c-erbB-2. Viruses containing the SLPI or the ubiquitously expressed CMV promoter, with or without sCARfC6.5, were used for infection of ovarian cancer cell lines, primary ovarian tumor cells, and in an orthotopic model of disseminated ovarian carcinoma. This dual-targeting strategy increased the efficiency and specificity of transgene expression in vitro in reporter and cell-killing assays, and in vivo. By using both the SLPI promoter and sCARfC6.5, transgene expression was increased in ovarian tumors and decreased in normal tissues, including the liver. Thus, we show that combining transcriptional and transductional targeting can increase the efficacy and specificity of adenoviral gene therapy for ovarian carcinoma.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Tomko RP, Xu R, Philipson L . The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsakieviruses. Proc Natl Acad Sci USA 1997; 94: 3352–3356.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Yang Y . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004–2015.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Yang Y . Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137–144.

    PubMed  Google Scholar 

  4. Bauerschmitz G, Barker S, Hemminki A . Adenoviral gene therapy for cancer – from vectors to targeted and replication competent agents. Int J Oncol 2002; 21(6): 1164–1174.

    Google Scholar 

  5. Curiel D . Strategies to adapt adenoviral vectors for targeted delivery. Ann NY Acad Sci 1999; 886: 158–171.

    Article  CAS  PubMed  Google Scholar 

  6. Kashentseva E et al. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 2001; 62: 609–616.

    Google Scholar 

  7. Agus D et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27: 53–63.

    CAS  PubMed  Google Scholar 

  8. Hung M, Lau Y . Basic science of HER-2/neu: a review. Semin Oncol 1999; 26: 51–59.

    CAS  PubMed  Google Scholar 

  9. Nettelbeck D, Jerome V, Muller R . Gene therapy: designer promoters for tumour targeting. Trends Genet 2000; 16: 174–181.

    Article  CAS  PubMed  Google Scholar 

  10. Barker S et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2002; (in press).

  11. Kanerva A et al. Gene transfer to ovarian cancer versus normal tissues with fiber modified adenoviruses. Mol Ther 2002; 5: 695–704.

    Article  CAS  PubMed  Google Scholar 

  12. Reynolds P et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotech 2001; 19: 838–842.

    Article  CAS  Google Scholar 

  13. Robertson M et al. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther 1998; 5: 331–336.

    CAS  PubMed  Google Scholar 

  14. Barker S et al. (2002). The regulatory sequences of the secretory leukoprotease inhibitor gene as a promising tissue-specific promoter for ovarian cancer gene therapy. In: American Society of Gene Therapy. Boston, MA.

  15. Barker S et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82: 57–63.

    Article  CAS  PubMed  Google Scholar 

  16. Raper S et al. A pilot study on in vivo-directed gene transfer with an adenoviral vector in partial orthinine transcarbamylase defiency. Hum Gene Ther 2002; 13: 163–175.

    Article  CAS  PubMed  Google Scholar 

  17. Casado E et al. Transcriptional targeting for ovarian cancer gene therapy. Gynecol Oncol 2001; 82: 229–237.

    Article  CAS  PubMed  Google Scholar 

  18. Qiao J et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Therapy 2002; 9: 168–175.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by the Sigrid Juselius Foundation, the Emil Aaltonen Foundation, the Maud Kuistila Foundation, the Finnish Medical Foundation, the Academy of Finland and the National Cancer Institute (CA83821, P50 CA83591, P50 CA89019), US Army Department of Defense (DAMD17-00-1–0115), and the Deutsche Forschungsgemeinschaft.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barker, S., Dmitriev, I., Nettelbeck, D. et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther 10, 1198–1204 (2003). https://doi.org/10.1038/sj.gt.3301974

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301974

Keywords

This article is cited by

Search

Quick links